FedEx Corp. (NYSE: FDX) Q2 2021 earnings call dated Dec. 17, 2020
Corporate Participants:
Mickey Foster — Vice President, Investor Relations
Frederick W. Smith — Chairman of the Board and Chief Executive Officer
Brie Carere — Executive Vice President, Chief Marketing and Communications Officer
Rajesh Subramaniam — President and Chief Operating Officer
Mike Lenz — Executive Vice President and Chief Financial Officer
Henry J. Maier — FedEx Ground President and Chief Executive Officer
Donald F. Colleran — FedEx Express President and Chief Executive Officer
Analysts:
David Ross — Stifel Nicolaus — Analyst
Brandon Oglenski — Barclays Capital — Analyst
Bascome Majors — Susquehanna International Group — Analyst
Scott Schneeberger — Oppenheimer & Co. Inc. — Analyst
Amit Mehrotra — Deutsche Bank — Analyst
Thomas Wadewitz — UBS — Analyst
Jack Atkins — Stephens Inc. — Analyst
Jordan Alliger — Goldman Sachs — Analyst
Scott Group — Wolfe Research, LLC — Analyst
Duane Pfennigwerth — Evercore ISI — Analyst
Allison Landry — Credit Suisse — Analyst
Brian Ossenbeck — JPMorgan — Analyst
Allison Poliniak — Wells Fargo Securities — Analyst
David Vernon — Sanford C. Bernstein — Analyst
_______
To read the full earnings call transcript, click here
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training